Clinical Scorecard: Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

At a Glance

Key Highlights

• Dual-target CD38/BCMA CAR-T therapy shows high overall response rate (89%) and complete response/stringent complete response rate (63%) in RRMM.
• Single-target CD38 CAR-T therapy demonstrates lower efficacy (33% ORR) and higher mortality (44%) compared to dual-target constructs.
• Common adverse events include cytokine release syndrome (83% any grade; 26% grade ≥3), infections (23%), neurotoxicity (13%), and kidney injury (13%).

Guideline-Based Recommendations

Diagnosis

• Confirm relapsed/refractory multiple myeloma diagnosis with clinical and laboratory criteria before considering CAR-T therapy.

Management

• Consider dual-target CD38/BCMA CAR-T therapy for RRMM patients, given its promising efficacy and manageable safety profile.
• Exercise caution with single-target CD38 CAR-T therapy due to limited evidence and higher mortality rates.
• Implement lymphodepletion and bridging regimens as per clinical trial protocols.

Monitoring & Follow-up

• Monitor patients closely for cytokine release syndrome (CRS), including grading severity and managing accordingly.
• Assess for immune effector cell-associated neurotoxicity syndrome (ICANS) and kidney injury during and after therapy.
• Regularly evaluate treatment response including overall response rate, complete response, and minimal residual disease status.

Risks

• High incidence of cytokine release syndrome, including severe cases (grade ≥3).
• Risk of infections and immune-related adverse events such as neurotoxicity.
• Potential kidney injury associated with therapy.

Patient & Prescribing Data

Patients with relapsed/refractory multiple myeloma enrolled in clinical trials of CD38-directed CAR-T therapy.

Dual-target CD38/BCMA CAR-T therapy yields higher response rates and lower mortality compared to single-target CD38 CAR-T; safety profile includes manageable CRS and neurotoxicity.

Clinical Best Practices

• Prefer dual-target CD38/BCMA CAR-T constructs over single-target CD38 CAR-T for improved efficacy and safety.
• Implement comprehensive monitoring protocols for CRS and neurotoxicity to promptly identify and manage adverse events.
• Use evidence-based patient selection criteria focusing on RRMM patients refractory to standard therapies.
• Encourage enrollment in larger comparative clinical trials to further define optimal treatment sequencing and long-term outcomes.

References

• PRISMA Guidelines